• Ontwikkelingsmaatschappij Oost-Nederland NV provided follow-on financing to GlycoTherapeutics to advance a new oncology drug candidate toward clinical preparation.
• GlycoTherapeutics develops compounds that inhibit specific sugars on cancer cells, aiming to curb tumor growth and improve immune recognition.
• The platform originated from more than a decade of research at Radboud University.
• The company reported promising preclinical results, secured multiple patents, plans portfolio expansion.
• Funding extends runway by about two years, supports development work, enables use of a Health~Holland subsidy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ontwikkelingsmaatschappij Oost-Nederland NV published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.